Trial document




drksid header

  DRKS00006878

Trial Description

start of 1:1-Block title

Title

Evaluation of the necessity of long-term pharmacological treatment with
antipsychotics for the prevention of relapse in long-term stabilized
schizophrenic patients: a randomized, single-blind, longitudinal trial

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The main objective of the trial is to evaluate for the first time, how long an antipsychotic relapse-prevention should be continued and to which time a patient with schizophrenia is protected enough, so that a withdrawal or reduction of the medication seems appropriate. Relapse is
defined as primary outcome.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The main objective of the trial is to evaluate for the first time, how long an antipsychotic relapse-prevention should be continued and to which time a patient is protected enough, so
that a guided withdrawal or reduction of the medication seems appropriate. Relapse is
defined as primary outcome. We include patients with schizophrenia or schizoaffective disorder in remission for at least 3 years under a stable antipsychotic medication.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00006878
  •   2014/11/06
  •   [---]*
  •   yes
  •   Approved
  •   353/14, Ethik-Kommission der Fakultät für Medizin der Technischen Universität München
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2013-000338-37 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   F20 -  Schizophrenia
  •   F25 -  Schizoaffective disorders
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Intervention group: guided discontinuation or dose-reduction of the current antipsychotic medication. The antipsychotic drug used before study start will be discontinued gradually under medical surveillance. The process of discontinuation depends on the physicians judgement und should be guided be the participants needs and clinical status. This approach was already used before in another study ("gradual discontinuation", Wunderink et al., 2007). We assume that the dose can be reduced by approximately 1/6 of the starting dose every two weeks. If long acting antipsychotics are applied, there is no need for a gradual discontinuation due to their long half life. After randomisation (start of the active study phase) no further depot medication will be applied. Study medication is, with exception of Clozapin, every oral or depot neuroleptic drug approved for the treatment of schizophrenia in Germany.
  •   Control group: The participants must be stable. They will receive the same antipsychotic drugs, they have received before the start of the study, without changing the dose or the application form. Study medication is, with exception of Clozapin, every oral or depot neuroleptic drug approved for the treatment of schizophrenia in Germany.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   assessor, data analyst
  •   Active control
  •   Treatment
  •   Parallel
  •   IV
  •   No
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Relapse is defined as primary outcome.
The criterion is measured at every visit (every two weeks) two weeks with two criteria, both have to be fullfilled:
a) Score ≥4 (moderate) for at least two of the following PANSS-items :
"Delusions" (P1), "Conceptual disorganisation" (P2), "Halluzinations" (P3), "Mannerisms and posturing" (G5) and "Unusual thought content" (G9) (PANSS; Kay et al., 1987)
b) Score ≥4 on the "Clinical Global Impression Severity Scale" (CGI-S; Guy, 1976b)

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Psychiatric rehospitalisation (every visit, every 2 weeks)
- Totalscore of Positive and Negative Syndrome Scale (PANSS)
(Baseline, then every 4 weeks)
- Occurence of specific adverse effects (open interview)
(Baseline,then every 4 weeks)
- Clinical Global Impression – Severity Scale (CGI-S)
(Baseline, then every 4 weeks)
- “Quality of life” measured by the questionnaire “Subjective well-being under neuroleptics scale” (SW-N) (Baseline, and after 12 and 26 weeks)
- Status of occupation (Baseline, and after 12 and 26 weeks)
- Personal and Social Performance (Personal and Social Performance Scale [PSP]) (Baseline, and after 12 and 26 weeks)
- Adherence/Attitude of patients towards medication (Medication Adherence Rating Scale [MARS]) (Baseline, and after 12 and 26 weeks)
- Drop-outs total and due to specific reasons
- Movement disorders (Abnormal Involuntary Movement Scale [AIMS]) (Baseline, and after 12 and 26 weeks)
- Weight change (Baseline, and after 12 and 26 weeks)

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Planned
  •   2014/12/01
  •   25
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   65   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- Male or female patients, 18 to 65 years of age.
- Diagnosis of schizophrenia or schizoaffective disorder.
- The participants have to be in remission for at least 3 years (i.e. no psychiatric
hospitalisation) under a stable antipsychotic medication. Remission will be measured using the remission criteria by Andreasen et al. (2005)
Score ≤3 for the items concerning psychosis of the "Positive and Negative Syndrom Scale" (PANSS; Kay et al., 1987):
"Delusions" (P1), "Conceptual disorganisation" (P2), "Halluzinations" (P3), "Mannerisms and posturing" (G5) and "Unusual thought content" (G9) and a score ≤3 on the "Clinical Global Impression Severity Scale" (CGI-S; Guy, 1976b)
- Able to give informed consent.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Actively suicidal.
- Serious medical illnesses.
- Known non-complience concerning the medication.
- Medication with clozapin.
- Medication with antidepressants and mood stabilisors that were initiated during the last 6 weeks before study enrollment.
- Patients with substance dependence other than nicotine or caffeine within 6 months prior to baseline.
- Unability to give informed consent.
- Pregnancy.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Klinikum rechts der Isar der TU München
    • Ismaninger Str. 22
    • 81675  München
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Klinik für Psychiatrie und PsychotherapieTechnische Universität MünchenKlinikum rechts der Isar
    • Mr.  Prof. Dr.  Stefan  Leucht 
    • Ismaninger Str. 22
    • 81675  München
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Klinik für Psychiatrie und PsychotherapieTechnische Universität MünchenKlinikum rechts der Isar
    • Mr.  Prof. Dr.  Stefan  Leucht 
    • Ismaninger Str. 22
    • 81675  München
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Deutsche Forschungsgemeinschaft
    • Kennedyallee 40
    • 53175  Bonn
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting planned
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.